Efavirenz is a highly effective HIV-1 antiretroviral; however, it is also frequently associated
with neuropsychiatric adverse events (NPAE) that include abnormal dreams, sleep …

ABSTRACT Introduction Adverse drug reactions (ADRs) are among the leading causes of
death, and frequently associated with drug–gene interactions (DGIs). In addition to …

Objectives We evaluated the importance of ethnicity and pharmacogenetic variations in
determining efavirenz pharmacokinetics, auto-induction and immunological outcomes in two …

CYP3A4, considered the most important enzyme in drug metabolism, is often involved in
drug-drug interactions. When developing new drugs, appropriate markers for detecting …

A key goal in the clinical development of a new molecular entity is to quickly identify whether
it has the potential for drug–drug interactions. In particular, confirmation of in vitro data in the …

We investigated the influence of efavirenz (EFV)-or nevirapine (NVP)-based antiretroviral
therapy (ART) on lumefantrine plasma exposure in HIV-malaria-coinfected patients and …

Background Pregnancy has considerable effects on the pharmacokinetic properties of drugs
used to treat uncomplicated Plasmodium falciparum malaria. The role of pharmacogenetic …

Background: Enzyme-inducing antiepileptic drugs (EIAEDs) are among the clinically most
important inducers of cytochrome P450 (CYP) 3A4, but there is limited evidence regarding …

A number of cytochrome P450 (CYP) 3A phenotyping probes have been used to
characterize the drug interaction potential of new molecular entities; of these, midazolam …

Background HIV-malaria co-infected patients in most parts of sub-Saharan Africa are treated
with both artemether-lumefantrine (AL) and efavirenz (EFV) or nevirapine (NVP)-based …